CA-NEXON-AMERICA-INC
MapleStory 2 , the newest leading free to play MMORPG in the illustrious and vibrant setting of Maple World, has officially hit 1 million account downloads, only a week after its launch. MapleStory 2 is available for download globally on Nexon Launcher and Steam .
Since its official launch, MapleStory 2 has become one of the biggest MMORPGs on Steam and a beloved game for 1 million players due to its unlimited customization, quests, and its fun community. Due to its rapid growth, the game continues to increase its servers, especially the Oceania server, where player population continues to exceed expectations.
To celebrate the occasion, MapleStory 2 will hold various events to commemorate the achievement and thank its players.
MapleStory 2 1 Million Player Celebration Events:
- Double Bonus Item Drop Event: Starting Friday, Oct. 19 and going until Friday, Oct. 26, players will be able to earn double bonus items from normal adventure dungeons.
- Special Weekend Login Event: Beginning Saturday, Oct. 20 until Monday, Oct. 22, players with Lv. 60 characters will have the opportunity to receive two gifts. Players who login between Saturday, Oct. 20 and Sunday, Oct. 21 will receive a Style Crate. Players who login between Sunday, Oct. 21 and Monday, Oct. 22 will receive 500 Red Merets. More details can be found here .
Starting today, MapleStory 2 is also hosting various Halloween themed quests, dungeons, and in-game contests until November 8. Players who solve the murder mystery at the Mon Bloody Chouchou Hotel and complete the Stamp Event can collect Pumpkin Coins and exchange them for special Halloween themed items. Lv. 10+ characters, can also obtain a “Pumky Nest” item in their house by completing quests for furnishing items. Players can claim rewards including the Bouncy Pumky Mount, Little Pumky Pet, and Perched Pumky.
To learn more about MapleStory 2 , please visit http://maplestory2.nexon.net .
Assets : MapleStory 2
Trailers:
MapleStory 2 Halloween
Trailer: https://youtu.be/i58HV_M4eg4
MapleStory
2 Gameplay Trailer: https://youtu.be/Xq57SbVorPY
MapleStory
2 Official Launch Trailer: https://youtu.be/whVoKizV0Mg
Social
Media
:
Twitch
/ Facebook
/ Twitter
/ YouTube
/ Instagram
About MapleStory 2 http://maplestory2.nexon.net/en
Set in a colorful 3D block universe, MapleStory 2 is one of the most creative and customizable MMORPGs available on the market today. MapleStory 2 implements a robust set of character options, a brand new progression and growth system, and world-building tools, redefining the MMORPG genre by giving players the ability to customize everything.
About Nexon America Inc. http://www.nexon.net
Nexon America, a subsidiary of NEXON Co., Ltd. (“Nexon”) (3659.TO), is a global leader in online games, with more than 100 live games operated across more than 190 countries. Nexon pioneered micro-transactions and the free-to-play business model, and is widely credited with unmatched global expertise in sophisticated live game operations, nurturing player communities, and for sustaining titles for years, even decades. Founded in Korea in 1994, the company is now headquartered in Japan and listed on the Tokyo Stock Exchange. In 2017, Nexon was placed on the Nikkei Stock Index 300.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181018005952/en/
Contact:
B/HI for Nexon Wahid Lodin wahid_lodin@bhimpact.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 Data for Incyte’s Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet13.6.2025 00:45:00 CEST | Press release
POD1UM-303/InterAACT 2 is the first and largest global Phase 3 trial evaluating a PD-1 inhibitor in combination with chemotherapy for the treatment of patients with advanced SCAC not previously treated with systemic chemotherapy The trial met its primary endpoint; treatment with retifanlimab in combination with platinum-based chemotherapy (carboplatin-paclitaxel) resulted in clinically meaningful improvements in progression-free survival and overall survival In May 2025, the U.S. Food and Drug Administration (FDA) approved Zynyz® (retifanlimab-dlwr) in combination with carboplatin and paclitaxel and as a single agent for the treatment of advanced SCAC; submissions to other global regulatory agencies are also under review Incyte (Nasdaq:INCY) today announced that primary results from the Phase 3 POD1UM-303/InterAACT 2 trial of retifanlimab (Zynyz®), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in combination with carboplatin and paclitaxel (platinum-base
Güntner Drives Group-Wide Innovation in 2024 Sustainability Report12.6.2025 21:30:00 CEST | Press release
Progress in natural refrigerants, water efficiency and circular economy underscores Güntner’s global impact Güntner, a global leader in refrigeration and heat exchange technology, today announced its featured role in the newly released 2024 A-HEAT Sustainability Report. The report outlines significant progress toward ambitious environmental goals—fueled by Güntner’s commitment to measurable, innovation-led sustainability. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612897493/en/ Güntner advances global sustainability goals with progress in natural refrigerants, water savings, and circular economy efforts. Working toward its 2030 sustainability targets, Güntner delivered significant achievements across key areas including natural refrigeration integration, water and energy efficiency and the development of circular economy solutions. These efforts reflect Güntner’s ongoing mission to make sustainability not just a goal,
Windsurf Launches First GPU Cluster in Germany, Expanding Secure Enterprise AI in Europe12.6.2025 20:45:00 CEST | Press release
Windsurf launches a GPU cluster in Germany, delivering 50% faster performance and secure access to European enterprises. Data residency ensures enterprise repositories stay within the EU, meeting stringent security requirements. Windsurf already supports 100+ European enterprise customers, highlighting strong demand for AI-powered development tools across EMEA. Windsurf, a leader in AI-powered software development, today announced its first GPU cluster in Germany, as product demand surges and the company expands performance capacity across the EU. With over 100 local enterprise customers already using Windsurf products, the new cluster marks the company’s first major international step in building scalable infrastructure for the European market. Located in Frankfurt, home to some of the world’s strictest data security laws, the cluster was a natural choice for Windsurf’s first deployment. This cluster was specifically designed to meet the unique security and performance requirements of
Xsolla Partners With Defold to Enable Seamless In-game Purchases for Web Developers12.6.2025 19:00:00 CEST | Press release
New SDK Integration Simplifies Monetization for Defold Developers Publishing on CrazyGames Ahead of Global Game Jam Xsolla, a leading global video game commerce company, announces a new strategic partnership with Defold, the cross-platform game engine trusted by professionals and indie developers worldwide. This collaboration introduces a seamless integration between Xsolla and Defold-built web games on CrazyGames, enabling developers to easily monetize their titles just in time for the CrazyGames x Defold Game Jam running June 13–15. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612569206/en/ (Graphic: Xsolla) To address the complexity of in-game monetization, Xsolla and Defold have developed a new SDK that allows Defold developers to implement in-game purchasing functionality without the complex manual API setup required. With Xsolla’s sponsorship and support, this integration removes friction from the monetization jou
Pioneering Cancer Plasticity Atlas will Help Predict Response to Cancer Therapies12.6.2025 17:00:00 CEST | Press release
The Wellcome Sanger Institute, Parse Biosciences, and the Computational Health Center at Helmholtz Munich today announced a collaboration to build the foundation of a single cell atlas, focused on understanding and elucidating cancer plasticity in response to therapies. The collaboration will catalyze an ambitious future phase to develop a cancer plasticity atlas encompassing hundreds of millions of cells. Utilizing novel organoid perturbation and Artificial Intelligence (AI) platforms, the aim is to create a comprehensive dataset to fuel foundational drug discovery models and cancer research. Dr. Mathew Garnett, Group Leader at the Sanger Institute, and Prof. Fabian Theis, Director of the Computational Health Center at Helmholtz Munich and Associate Faculty at the Sanger Institute, will be the principal investigators in the collaboration. Garnett’s research team has generated novel 3D organoid cultures that serve as highly scalable and functional cancer models with the ability to capt
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom